TITUSVILLE, NEW JERSEY, April 27, 2026

Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) for CAPLYTA® (lumateperone), supported by robust Phase 3 data demonstrating a significant reduction in relapse risk in adults with schizophrenia. The approval marks a critical advancement in long-term disease management, with clinical data showing that CAPLYTA reduced relapse risk by 63% and kept 84% of patients relapse-free over six months, reinforcing its role as a key therapy in neuropsychiatric treatment.

FDA Approval Backed by Strong Phase 3 Clinical Evidence

The FDA approval is based on a Phase 3, randomized, double-blind withdrawal study demonstrating statistically significant improvements in time to relapse compared to placebo, highlighting CAPLYTA’s ability to provide long-term stability for patients with schizophrenia. The study showed that patients treated with CAPLYTA experienced a substantially delayed relapse onset and reduced treatment discontinuation rates, addressing one of the most critical challenges in managing chronic psychiatric disorders.

Relapse remains a major concern in schizophrenia, often leading to hospitalization, reduced functioning, and increased healthcare burden, with patients experiencing multiple relapse episodes over time. CAPLYTA’s ability to significantly lower relapse risk offers clinicians a powerful tool to improve patient outcomes, reduce disease burden, and enhance long-term treatment adherence. Importantly, the therapy maintained a consistent safety profile with no new safety concerns identified, further strengthening its clinical utility.

Advancing Long-Term Stability in Neuropsychiatric Care

Advertisement

cGxPJobs Banner

CAPLYTA is an oral, once-daily atypical antipsychotic with a differentiated pharmacological profile, characterized by high serotonin receptor activity and moderate dopamine receptor engagement, which may contribute to its efficacy and tolerability. Unlike many traditional antipsychotics, CAPLYTA demonstrated minimal impact on weight, metabolic parameters, and extrapyramidal symptoms, which are common reasons for treatment discontinuation.

Long-term extension data further support its safety and tolerability, with patients showing stable or improved metabolic outcomes and minimal adverse effects over extended treatment periods. This is particularly important in schizophrenia management, where treatment adherence and tolerability are critical to preventing relapse and maintaining patient stability.

Schizophrenia affects approximately 2.8 million adults in the United States and remains significantly undertreated, with a substantial proportion of patients not receiving adequate care. The economic burden of the disease is also considerable, emphasizing the need for therapies that can reduce relapse rates, improve quality of life, and lower healthcare costs.

Strengthening Johnson & Johnson’s Neuroscience Portfolio

This sNDA approval further strengthens Johnson & Johnson’s leadership in neuroscience and innovative medicine, expanding its portfolio of therapies aimed at addressing complex mental health conditions. CAPLYTA is already approved for multiple indications, including major depressive disorder and bipolar depression, and continues to be evaluated in additional neuropsychiatric and neurological disorders.

The label update reinforces the importance of evidence-based, patient-centered treatment strategies, focusing not only on symptom control but also on long-term disease stability and relapse prevention. From a cGxP perspective, the approval highlights the critical role of clinical trial rigor, regulatory compliance, and pharmacovigilance in bringing safe and effective therapies to market.

By demonstrating strong clinical outcomes and a favorable safety profile, CAPLYTA positions itself as a leading option in schizophrenia treatment, offering hope for improved patient outcomes and more sustainable disease management strategies.

Source: Johnson & Johnson press release